AbbVie (NYSE:ABBV) Price Target Raised to $190.00 at UBS Group
AbbVie (NYSE:ABBV – Get Free Report) had its price target lifted by equities researchers at UBS Group from $181.00 to $190.00 in a note issued to investors on Monday,Benzinga reports. The brokerage ...
AbbVie (NYSE:ABBV) Price Target Raised to $215.00 at BMO Capital Markets
AbbVie (NYSE:ABBV – Get Free Report) had its price objective lifted by equities research analysts at BMO Capital Markets from ...
Hosted on MSN6h
Is Wall Street Bullish or Bearish on AbbVie Stock?
Valued at a market cap of $336 billion, AbbVie Inc. (ABBV) is a global biopharmaceutical company dedicated to developing ...
The Armenian Reporter2h
Groesbeck Investment Management Corp NJ Boosts Position in AbbVie Inc. (NYSE:ABBV)
Groesbeck Investment Management Corp NJ lifted its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 168.6% during the 4th quarter, according to its most recent disclosure with the Securities & ...
The Armenian Reporter6h
AbbVie Inc. (NYSE:ABBV) Shares Acquired by Tanager Wealth Management LLP
Tanager Wealth Management LLP increased its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 20.5% in the 4th quarter, ...
Hosted on MSN19h
Pfizer's Covid Products Drove Its Fourth-Quarter Upside. But Is It Sustainable?
Pfizer tock edged lower Tuesday on a "pretty uneventful quarter" as revenue from its Covid products helped drive a fourth-quarter beat.